stathmin基因的表达与长春瑞滨治疗非小细胞肺癌疗效关系  

The relationship between expression of stathmin and therapeutic effect of vinorelbin on non-small cell lung cancer

作　　者：蒲骁麟[1] 王峻[1] 俞明峰[2] 马俊青[3] 王子露[3] 刘福银[1] 樊卫飞[1] 杨明[1] 孟丽娟[1] 

机构地区：[1]江苏省省级机关医院肿瘤科,江苏南京210024 [2]江苏省肿瘤医院胸外科,江苏南京210029 [3]南京医科大学附属口腔医院中心实验室,江苏南京210021

出　　处：《中国癌症杂志》2008年第10期755-759,共5页China Oncology

基　　金：江苏省卫生厅科技发展课题基金(No:H200621)。

摘　　要：背景与目的:化疗是晚期非小细胞肺癌(NSCLC)的主要治疗手段,但是NSCLC常对化疗耐药,导致治疗失败。因此,针对不同分子生物学特点的NSCLC进行化疗疗效预测,成为提高疗效的重要方法。本研究通过研究晚期NSCLC患者肿瘤组织中Stathmin基因的表达与患者对长春碱类药物的化疗敏感性的关系,为患者选择适当的药物治疗提供依据。方法:2005年5月—2007年12月,共78例晚期NSCLC患者入组,随机分入NP方案[长春瑞滨(NVB)联合顺铂(DDP)或卡铂(CBP)]化疗组或GP方案[吉西他滨(GEM)联合DDP或CBP]化疗组,观察两组对化疗的反应;同时以RT-PCR法检测患者病理组织中StathminmRNA的表达,以Western印迹法检测Stathmin的蛋白含量。结果:NP组41例,GP组37例,两组患者的性别、年龄、病理类型及肿瘤分期等临床特点无显著性差异(P>0.05),对化疗总的有效率分别为46.3%(19/41)和48.6%(18/37),两者之间亦未见显著差异(P>0.05);在NP组内,有效19例,无效22例,有效患者的肿瘤组织中stathminmRNA测量值为1.9±1.1,而无效患者为7.5±2.8,两者之间差异有显著性(P=0.003)。有效患者的Stathmin蛋白测量值为1.5±0.7,无效组为4.3±1.6,两者之间差异有显著性(P=0.002)。GP组18例有效,19例无效,有效与无效患者肿瘤组织中stathminmRNA及Stathmin蛋白无明显差异(P>0.05)。结论:NSCLC患者肿瘤组织中stathmin基因的表达与患者对长春碱药物的敏感性有关,stathmin基因高表达,对长春碱药物的敏感性低,宜换用其他药物治疗。Background and purpose：Chemotherapy is a main method for advanced non-small cell lung cancer（NSCLC）, but drug-resistance is frequently one of the reasons for the failure of the treatment. Predicting the effi cacy of chemotherapy based on different molecular characteristic of NSCLC is an important way to improve the outcome of the treatment.Our research was to study the role of stathmin gene expression in the treatment response with vinorelbin for non-small cell lung cancer,which would provide a basis of the individualized treatment for the patients. Methods：From May,2005 to December,2007, 78 advanced NSCLC patients accepted chemotherapy of Vinorelbine＋Cisplatin/Carboplatin （NP） or Gemcitabin＋Cisplatin/Carboplatin（GP） randomly. RT-PCR technology and Western blot were used to examine mRNA and protein level of stathmin gene for the patients. Results：41 patients were treated with NP and 37 with GP. There were no statistic differences between the two group patients in clinicalcharacteristics of age,gender,pathological type and disease stage（P〉0.05）.The responses rate of the two groups were 46.3%（19/41） and 48.6%（18/37） respectively. No statistic difference could be seen in this two groups（P〉0.05）.In NP group,Stathmin mRNA levels in 19 patients with responses compared with 22 patients with no responses were 1.9±1.1 vs 7.5±2.8 （P=0.003）; the level of Stathmin protein in 19 patients with responses compared with 22 patients with no responses were 1.5±0.7 vs 4.3±1.6 （P=0.002）. In the GP group, there were no significant difference between these patients with responses to the treatment or not in terms of stathmin mRNA and protein level（P〉0.05）. Conclusion： The expression of stathmin gene in NSCLC had been found in association with the sensitivity of the patients treated by vinblastine alkaloid. Patients with high level of stathmin gene expression would have poor responses to this cytotoxic drug.

关 键 词：STATHMIN 非小细胞肺癌 化疗 WESTERN印迹法 MRNA 

分 类 号：R734.2[医药卫生—肿瘤] R720.53[医药卫生—临床医学]